Top Qs
Timeline
Chat
Perspective

Bimekizumab

Monoclonal antibody From Wikipedia, the free encyclopedia

Remove ads

Bimekizumab, sold under the brand name Bimzelx (/bɪmˈzɛlɪks/ bim-ZEL-iks), is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody[6][7] that is used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa.[6]

Quick Facts Monoclonal antibody, Type ...

The most common side effects include upper respiratory tract infections (nose and throat infection) and oral candidiasis (thrush, a fungal infection in the mouth or throat).[6] Injection site reactions were also common, reported in 3% of subjects.[8]

Bimekizumab was approved for medical use in the European Union in August 2021,[6][9][10] and in the United States in October 2023.[11][12]

In November 2024, bimekizumab was approved by the US Food and Drug Administration for the treatment of active moderate-to-severe hidradenitis suppurativa in adults.[13]

Remove ads

Medical uses

In the EU, bimekizumab is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, non-radiographic axial spondyloarthritis, and active ankylosing spondylitis.[6]

Society and culture

Names

Bimekizumab is the international nonproprietary name (INN).[14]

Research

Phase III trials have demonstrated that bimekizumab is superior to not only adalimumab[15] but also secukinumab[16] and ustekinumab[17] for the treatment of plaque psoriasis.

The approval for the treatment of active moderate-to-severe hidradenitis suppurativa (HS) in adults was supported by data from two Phase 3 studies, BE HEARD I and BE HEARD II, which evaluated the efficacy and safety of bimekizumab in the treatment of adults with moderate-to-severe HS.[18][19][20]

References

Further reading

Loading related searches...

Wikiwand - on

Seamless Wikipedia browsing. On steroids.

Remove ads